Question · asked by 1 review
Anti‐VEGF vs no anti‐VEGF: Adverse events assessed in various ways, up to 24 months
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐VEGF vs no anti‐VEGF Proportion of participants with adverse events at various · people with neovascular glaucoma Anti‐vascular endothelial growth factor for neovascular glaucoma (2023) · Cochrane Headline outcomes only | no estimate extracted | 6 participants | GRADE not reported |
Anti‐VEGF medications vs no anti‐VEGF medications Proportion of participants with adverse events various · people with neovascular glaucoma Anti‐vascular endothelial growth factor for neovascular glaucoma (2020) · Cochrane Headline outcomes onlyearlier version CD007920.PUB3, superseded | no estimate extracted | 4 studies · 263 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐vascular endothelial growth factor for neovascular glaucoma 2023 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.